Number_reference_aid_programme: SA.41471(2015/X) Purpose of public aid: Article 25 of Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty That’s it. EU L 187/1 of 26.06.2014). Chronic pain disorders are associated with increasingly frequent civilisation diseases and physical injuries. The mechanism of chronic pain formation is poorly understood, but disturbed pain sensations are believed to have no physiologically significant function and should be alleviated to improve the quality of life of sufferers. CPL207280 is a specific and powerful GPR40 receptor agonist. It is developed by Celon Pharma S.A as a drug against type 2 diabetes and has successfully passed the first phase of clinical trials, proving its effectiveness in preclinical studies on animal models. For this purpose, it received a patent in Poland and became the subject of an international patent. The molecule, unlike the competition, has a favorable safety profile, which in combination with the ability to overcome the blood-brain barrier allows it to be active in the nervous system. Recent scientific findings report that GPR40 agonism is key in modifying inflammatory and neuropathic pain. In addition, Celon Pharma S.A. has gathered evidence that GPR40 also plays a role in regulating diabetes-related neuropathic pain. In this project, the scope of the analgesic molecule CPL207280 will be examined in order to be able to find even wider use in pain indications for it, thus providing a drug addressing unmet medical and market needs. The project will carry out in vivo efficiency studies, biomarkers, nervous system safety. [...]